News
Article
Screening Experience of Phase 2 Autonomy Study Provides Insights for Anti-Tau Trials in Alzheimer Disease
Author(s):
Key Takeaways
- The Autonomy trial used plasma biomarkers for prescreening, linking tau PET SUVr to clinical outcomes in Alzheimer's disease.
- Posdinemab, a monoclonal antibody, demonstrated safety, tolerability, and dose-dependent reductions in p-tau217 in phase 1 studies.
In total, more than half of the screened population failed by not meeting plasma p-tau217 criteria and of the remaining, most participants were not in the intermediate tau PET range.
Maggie Fedgchin, PharmD
In the phase 2 Autonomy trial (NCT04619420), a study assessing an anti-phosphorylated tau (ptau) agent posdinemab (Janssen) in early Alzheimer disease (AD), investigators reported several lessons learned from the screening experience of the study, which is the first to employ a plasma biomarker as a prescreening tool. All told, baseline tau PET standardized uptake value ratio (SUVr) was linked to clinical outcomes across multiple brain areas, especially impacting immediate memory, language, and delayed memory.1
These findings were reported in a poster presented at the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference, held October 29-November 1 in Madrid, Spain. Autonomy, an ongoing, double-blind, placebo-controlled, randomized, parallel-group, common-close study, assesses the effect of 2 doses of posninemab (low or high dose) or placebo, every 4 weeks, for a 104-week period. Patients were eligible to enter the study if they had early symptomatic AD and met clinical and plasma p-tau217 criteria followed by intermediate levels of tau burden on tau PET.
Led by study investigator Maggie Fedgchin, PharmD, director of Neuroscience Clinical Development at Johnson & Johnson, the study screened 2670 participants across 115 sites, with 523 of these selected. Among the 80.4% of patients who failed the screening process, 58.6% did not meet plasma p-tau217 criteria. For the remaining 41.4%, 31.4% were not in the intermediate tau PET range (15.2% were tau PET negative, 16.2% had widespread tau).
Within the intermediate tau PET range, 44.7% were in the low and 55.3% were in the high tau strata. In addition, baseline tau PET SUVr correlated with baseline Alzheimer’s Disease Assessment Cognitive subscale 13 (ADAS-Cog13) score in various regions of interest (rs = 0.35-0.38; P <.01), and the strongest correlation with tau PET was baseline Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) immediate memory domain score with the total cortex region of interest (rs = 0.41; P <.010). Coming into the study, all 522 participants who received at least 1 dose of blinded treatment had screening Clinical Dementia Rating (CDR) global score of 0.5.
Previously known as JNJ-63733657, posdinemab is a humanized IgG1 monoclonal antibody that binds with high affinity to PHF tau and very weakly to non-ptau. The parent molecule of the agent, PT3, was raised against AD brain purified PHF, and preclinical studies with the humanized version, posdinemab, having demonstrated reductions in tau seeding. The mid-domain region where posdinemab binds differs from that of other anti-tau monoclonal antibodies that target the N-terminus.
READ MORE: Risk of ARIA-E in Donanemab Attenuated Through New Enhanced Titration Method of Delivery
The mean population age of Autonomy was 71.4 years, with most patients reporting as White (78.4%) and some (11.1%) as Hispanic. The screening analysis showed that prodromal AD accounts for 56.4% of the clinical diagnoses and 58% of the population was taking acetylcholinesterase inhibitors/memantine at baseline.
At baseline, patients had a mean Modified integrated Alzheimer’s Disease Rating Scale (iADRS) total score, the primary end point, of 101.8 (SD, 11.8). Regarding secondary end points, the mean baseline scores on ADAS Cog13 were 25.18 (SD, 7.98), 41.91 (SD, 6.27) for Alzheimer’s Disease Cooperative Study–Activities of Daily Living for Mild Cognitive Impairment (ADCS-ADL-MCI), 71.56 (SD, 13.26) for RBANS, 57.36 (SD, 16.60) for RBANS DMI, and 2.89 (SD, 1.15) for CDR-sum of boxes.
Recently, in early September, a published analysis examined the tolerability, safety, pharmacokinetics, immunogenicity of posdinemab in phase 1 studies that featured healthy participants and participants with prodromal or mild AD. Assessing both single and multiple doses of posdinemab, results showed that the therapy was safe and well-tolerated in both patient populations. In healthy participants and those with AD, posdinemab demonstrated linear pharmacokinetics, and serum Cmax and area under the operating curve were approximately dose proportional following single and multiple doses. Notably, dose-dependent reductions in free and total p-tau217 in cerebrospinal fluid were observed.2
Click here for more CTAD 2024 coverage.
